Search Result

Results for "

survival rate

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (1) Antibiotic (1) Apoptosis (1) Bacterial (3) Bcl-2 Family (1) Biochemical Assay Reagents (1) Calcium Channel (1) Cytochrome P450 (1) Dengue Virus (1) DNA Methyltransferase (1) DNA/RNA Synthesis (2) Drug Metabolite (2) Endogenous Metabolite (3) FAK (1) Flavivirus (1) Glutathione Peroxidase (2) HDAC (2) HIV (1) ICMT (1) Influenza Virus (2) Interleukin Related (4) JAK (1) MDM-2/p53 (1) Microtubule/Tubulin (1) MyD88 (1) Natriuretic Peptide Receptor (NPR) (1) NF-κB (4) NOD-like Receptor (NLR) (2) P-glycoprotein (2) p38 MAPK (2) Parasite (2) Phosphatase (1) Reactive Oxygen Species (1) SGLT (1) Sirtuin (1) SOD (1) Tau Protein (1) TNF Receptor (2) Toll-like Receptor (TLR) (1) TRP Channel (1) Virus Protease (1)
By Research Areas:	Cancer (13) Cardiovascular Disease (4) Endocrinology (1) Infection (10) Inflammation/Immunology (8) Metabolic Disease (1) Neurological Disease (6)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N12706

Heilaohuguosu G	Endogenous Metabolite	Endocrinology
Heilaohuguosu G (compound 7) is a cyclolignan with hepatoprotective activity. Heilaohuguosu G against APAP toxicity with cell survival rates at 10 μM of 45.7% in HepG-2 cells .

HY-122672A

Adhesamine diTFA	FAK	Neurological Disease
Adhesamine diTFA is a dumbbell-shaped molecule that activates the MAPK/FAK pathway. Adhesamine promotes the adhesion and growth of mammalian cells, accelerates the differentiation of primary cultured mouse hippocampal neurons, and enhances their survival rate .

HY-P99664

Inolimomab	Interleukin Related	Inflammation/Immunology
Inolimomab is an anti-interleukin-2 receptor (IL-2R) α chain monoclonal antibody. Inolimomab improves the survival rate in the early research of treating acute graft-versus-host disease (aGVHD) .

HY-173344

DB-10	p38 MAPK	Neurological Disease
DB-10 is a pro-agent of 3-nbutylphthalide (NBP) (HY-B0647). DB-10 has significantly high uptake ability via pyrilamine cationic transporters in the temperature and energy dependent manner in cells. DB-10 improves the survival rate of cells. DB-10 could rapidly convert into active original agent and increase the accumulation in the brain in vivo. DB-10 can be used for ischemic stroke study .

HY-W588247

S-(N-Methylsulfinylbutylthiocarbamoyl)-L-cysteine SF-cysteine	Drug Metabolite	Cancer
S-(N-Methylsulfinylbutylthiocarbamoyl)-L-cysteine (SF-cysteine), a metabolite of Sulforaphane (HY-13755), can enhance the survival rate of Nalm-6 cells .

HY-116117

Salicylcurcumin	SOD Glutathione Peroxidase	Others
Salicylcurcumin is a synthetic curcumin analogue with antioxidant activity. Salicylcurcumin may affect lipid peroxidation in fish, favoring increased survival, disease resistance, and ultimately growth rate .

HY-W666088

(2-Phenylethyl)hydrazine dihydrochloride	Biochemical Assay Reagents	Others
(2-Phenylethyl)hydrazine (dihydrochloride) is a compound with protective effects against γ-radiation. At a dose of 60 mg/kg, it can increase the survival rate of mice exposed to γ-radiation .

HY-B2085

Arsthinenol Arsthinol; Balarsen	Others	Cancer
Arsthinenol is an orally active antitumor agent, that exhibits cytotoxicity in U87MG cells with an IC₅₀ of 31.6 μM. Arsthinenol forms complex with cyclodextrin, inhibits the tumor growth and improves the survival rates of U87MG xenograft mice .

HY-119261

Ruboxyl	Antibiotic	Cancer
Ruboxyl is an anthracycline antibiotic with antitumor activity. Ruboxyl inhibits colorectal cancer (CRC) liver metastasis in mice by 84%, suppresses B16 melanoma growth, and increases the survival rate of mice with L1210 or L5178Y leukemia .

HY-117146

Indoxacarb (S)-DPX-JW062	Parasite	Infection
Indoxacarb ((S)-DPX-JW062) is an oxathiazole insecticide with activity against a wide range of insect pests. Indoxacarb is used in forest pest management to control insect pests, and its toxicity has significant effects on adult individuals of the predatory stink bug Podisus distinctus. Indoxacarb showed high toxicity to P. distinctus at a lethal concentration (LC50 = 2.62 g L-1). Indoxacarb treatment significantly reduced the survival rate of P. distinctus, with the survival rate of individuals exposed to 2.62 g L-1 decreasing to 40.7%. Indoxacarb also reduced the respiration rate of P. distinctus from 18.45 to 14.41 μL CO2 h-1, and inhibited its food intake. P. distinctus showed hyperexcitatory responses after Indoxacarb treatment .

HY-164031

Cloperidone	Cytochrome P450	Cancer
Cloperidone is an inhibitor for cytochrome P450 2C9 (CYP2C9) with an IC₅₀ of 17.7 μM. Cloperidone exhibits cytotoxicity on HepG2 cells expressing CYP2C9 (60% survival rate at 10 μM) .

HY-P2251

T-peptide	HIV Microtubule/Tubulin	Infection Inflammation/Immunology Cancer
T-peptide, a Tuftsin analog, can be used for the research of human immunodeficiency virus (HIV) infection. T-peptide prevents cellular immunosuppression and improves survival rate in septic mice. T-peptide also can inhibit the growth of residual tumor cells after surgical resection .

HY-P10279

Anaritide Human atrial natriuretic factor (102–126)	Natriuretic Peptide Receptor (NPR)	Cardiovascular Disease Others
Anaritide is a synthetic form of atrial natriuretic peptide (ANP) composed of 25 amino acids. Anaritide increases glomerular filtration rate by dilating into and contracting out the bulbar arterioles. Anaritide can be used to study the effects on patients with acute tubular necrosis, particularly in improving dialysis free survival .

HY-149708

UCM-13207	ICMT	Others
UCM-13207 (compound 21) is a selective ICMT inhibitor that ameliorates basic progeria-like features. UCM-13207 can improve the survival rate of LmnaG609G/G609G mice in the mouse premature aging model .

HY-N0633

Muscone 3 Publications Verification	P-glycoprotein Interleukin Related TNF Receptor NF-κB NOD-like Receptor (NLR)	Cardiovascular Disease Inflammation/Immunology
Muscone is the main active monomer of traditional Chinese medicine musk. Muscone inhibits NF-κB and NLRP3 inflammasome activation. Muscone remarkably decreases the levels of inflammatory cytokines (IL-1β, TNF-α and IL-6), and ultimately improves cardiac function and survival rate .

HY-155682

Antibacterial agent 150	Bacterial	Infection
Antibacterial agent 150 (compound 5g) is an antibacterial agent with potent antibacterial activity against both Gram-positive bacteria and Gram-negative bacteria (MIC values ranging from 1-32 μg/mL). Antibacterial agent 150 can increase survival rate of MRSA (Methicillin-resistant Staphylococcus aureus)-infected mice .

HY-168928

Antibiofilm agent prodrug 1	Bacterial	Infection
Antibiofilm agent prodrug 1 (Compound 5c) exhibits antibacterial activity through inhibition of biofilm formation and iron uptake. Antibiofilm agent prodrug 1 inhibits P. aeruginosa PAO1 with a MIC of 1.07 μM. Antibiofilm agent prodrug 1 exhibits anti-infectious efficacy in C. elegans with improved survival rate .

HY-163803

CM-444	HDAC DNA Methyltransferase	Cancer
CM-444 is inhibitor for HDAC (IC₅₀ is 6 nM-0.6 μM) and DNA methyltransferases (DNMT, IC₅₀ is 1.8-2.3 μM). CM-444 is an inducer for the differentiation of acute myeloid leukemia cells. CM-444 exhibits anti-leukemic activity and improves the survival rate in mouse models .

HY-108786

Asfotase alfa ENB-0040	Phosphatase	Metabolic Disease
Asfotase alfa (ENB-0040) is a bone-targeted genetically engineered glycoprotein. Asfotase alfa increases the survival rate, bone mineralization and bone length and prevents mineralization defects of the feet, rib cage, lower limbs, jaw bones in Akp2 ^/ knockout mice. Asfotase alfa can be used for the research of perinatal, infantile, and juvenile-onset hypophosphatasia (HPP) .

HY-N7922

Urolithin M5 Decarboxyellagic acid	Influenza Virus	Infection
Urolithin M5 is a neuraminidase inhibitor that can be isolated from Ganlanye. Urolithin M5 has antiviral activity in vitro and in vivo by inhibiting the activity of viral NA. Urolithin M5 can increase the survival rate and improve pulmonary edema in pr8-infected mouse models. Urolithin M5 can be used in anti-influenza research .

HY-W781133

cDPCP cis-[Pt(NH3)2(N1-pyridine)Cl]Cl	Others	Cancer
cDPCP (cis-[Pt(NH3)2(N1-pyridine)Cl]Cl) is a DNA crosslinking agent and also a substrate for OCT1 and OCT2. DPCP exhibits anticancer activity and can improve the survival rate of sarcoma-180 mice. cDPCP is suitable for the research of colorectal cancer and cancers with appropriate cation transporters .

HY-144612

NS2B/NS3-IN-2	Flavivirus Dengue Virus Virus Protease	Infection
NS2B/NS3-IN-2 is a potent dengue virus (DENV) NS2B/NS3 covalent inhibitor with an IC₅₀ of 6.0 nM and K_i of 0.66 µM. NS2B/NS3-IN-2 shows no cytotoxicity and markedly increases the cell survival rate .

HY-N0633R

Muscone (Standard)	P-glycoprotein Interleukin Related TNF Receptor NF-κB NOD-like Receptor (NLR)	Cardiovascular Disease Inflammation/Immunology
Muscone (Standard) is the analytical standard of Muscone. This product is intended for research and analytical applications. Muscone is the main active monomer of traditional Chinese medicine musk. Muscone inhibits NF-κB and NLRP3 inflammasome activation. Muscone remarkably decreases the levels of inflammatory cytokines (IL-1β, TNF-α and IL-6), and ultimately improves cardiac function and survival rate .

HY-169197

D-688	Tau Protein Amyloid-β	Neurological Disease
D-688 is an inhibitor of Tau and Aβ. D-688 can reverse Aβ1–42-induced toxicity in SH-SH5Y cells and has significant neuroprotective properties. D-688 can improve the survival rate of Drosophila melanogaster expressing the human tau protein isoform (2N4R) .

HY-P2818

Alkaline phosphatase, Bovine intestine 1 Publications Verification Apase	Endogenous Metabolite Glutathione Peroxidase Bacterial	Infection Inflammation/Immunology
Alkaline phosphatase, Bovine intestine (Apase) is an orally active membrane-bound glycoprotein that catalyzes the hydrolysis of phosphate monoesters at alkaline pH. Alkaline phosphatase, Bovine intestine reduces myeloperoxidase activity and bacterial translocation. Alkaline phosphatase, Bovine intestine improves survival rate of mice infected with E. coli. Alkaline phosphatase, Bovine intestine improves TNBS-induced colon inflammation .

HY-101780A

Tinostamustine hydrochloride EDO-S101 hydrochloride; NL-101 hydrochloride	HDAC	Cancer
Tinostamustine hydrochloride (EDO-S101 hydrochloride) is a compound with anti-multiple myeloma activity and the ability to promote CD38 expression. Tinostamustine hydrochloride enhances the sensitivity of tumor cells to the anti-CD38 monoclonal antibody daratumumab by increasing the acetylation level of histone H3. Tinostamustine hydrochloride can increase the expression of MICA and MICB, thereby activating NK cells. Tinostamustine hydrochloride can significantly delay tumor growth and improve the survival rate of mice .

HY-171180

AF615	DNA/RNA Synthesis	Cancer
AF615 is a small molecule inhibitor targeting the CDT1/Geminin protein complex (IC₅₀ = 0.313 μM). AF615 selectively induces DNA damage, inhibits DNA synthesis, causes cell cycle arrest, and decreases the survival rate in cancer cell lines. AF615 displayed a K_i = 0.37 μM in case of Geminin-tCDT1 interaction and a K_i = 0.75 μM in case of Geminin-miniCDT1 interaction .

HY-157892

Antimalarial agent 38	Parasite	Infection
Antimalarial agent 38 (Compound 1) exhibits activity against antiplasmodial, which inhibits Plasmodium falciparum D6 strain, chloroquine-sensitive Thai strain and chloroquine-resistant FcB1 strain and K1 strain, with IC₅₀s of 0.5, 13, 1 and 13 μM, respectively. Antimalarial agent 38 is non-cytotoxic for mammalian cells MCR58 (IC₅₀ >140 μM). Antimalarial agent 38 improves the survival rate of Plasmodium yoelii nigeriensis infected mouse model .

HY-156519

ALPK1-IN-3	NF-κB	Inflammation/Immunology
ALPK1-IN-3 is an inhibitor of ALPK1 extracted from patent WO2022063153A1 compound T007. ALPK1-IN-3 inhibits kidney proinflammatory gene expression and improves the survival rate of the animals in sepsis induced acute kidney injury animal model . ALPK1-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-100591

SirReal2 2 Publications Verification	Sirtuin	Neurological Disease Inflammation/Immunology Cancer
SirReal2 is a potent, isotype-selective Sirt2 inhibitor with an IC₅₀ value of 140 nM and has very little effect on the activities of Sirt3-5. SirReal2 leads to tubulin hyperacetylation in HeLa cells and induces destabilization of the checkpoint protein BubR1. SirReal2 combined with VS-5584 (HY-16585) suppresses tumor growth and extends the survival rate of mice in tumor xenograft model. SirReal2 is is promising for research of cancer, inflammation and neurodegeneration .

HY-105271

S-312-d S-(+)-S-312-d	Calcium Channel	Others
S-312-d (S-(+)-S-312-d) is a calcium channel blocker with the activity of protecting the kidney from ischemic acute renal failure. S-312-d (0.01-0.1mg/kg b.wt. iv) administered before ischemia has a dose-dependent protective effect on ischemia-induced renal damage, improves the survival rate of ischemic rats, and reduces renal cortical edema and the increase in renal tissue calcium content.

HY-17638A

Mizagliflozin (sebacate) DSP-3235 (sebacate); KGA-3235 (sebacate); GSK-1614235 (sebacate)	SGLT	Neurological Disease
Mizagliflozin sebacate (DSP-3235 sebacate) is a sodium-glucose cotransporter inhibitor with activity in improving vascular cognitive impairment caused by small vessel disease. Mizagliflozin sebacate improves blood flow and reverses vascular cognitive impairment by inhibiting neuronal SGLT1 activity. Mizagliflozin sebacate also showed the ability to increase the survival rate of IL-1β-treated PC12HS cells. Mizagliflozin sebacate promotes improvements in spatial learning and memory caused by small vessel disease in mouse models .

HY-173221

MJ210	NF-κB p38 MAPK Reactive Oxygen Species	Neurological Disease
MJ210 is a modulator of the NF-κB and MAPK pathways with oral activity and the ability to penetrate the blood-brain barrier, and it exhibits neuroprotective activity. In vitro, 5 μM of MJ210 can increase the survival rate of SH-SY5Y cells treated with Rotenone (HY-B1756) to 81.9% and reduce the level of ROS, etc. In vivo, 5 mg/kg of MJ210 can improve the motor impairment in a rat model of Parkinson's disease. MJ210 can be used in the research of neurological diseases, such as Parkinson's disease .

HY-W344074

Cytarabine 5’-monophosphate	DNA/RNA Synthesis Drug Metabolite	Cancer
Cytarabine 5′-monophosphate is a metabolite of the nucleoside analog Cytarabine (HY-13605), catalyzed by deoxycytidine kinase. Cytarabine 5′-monophosphate is incorporated into DNA by DNA polymerase α, which reduces the rate of DNA synthesis. At a concentration of 15 mM, Cytarabine 5′-monophosphate inhibits nuclear and mitochondrial DNA replication in Saccharomyces cerevisiae (S. cerevisiae). Additionally, Cytarabine 5′-monophosphate (3.5-75.1 mg/kg) improves survival in leukemia mice (L1210 mice). Cytarabine 5′-monophosphate can be used in cancer research .

HY-162492

Influenza A virus-IN-14	Influenza Virus	Infection
Influenza A virus-IN-14 (Compound 37) is an inhibitor for influenza virus type A (IAV), which inhibits H1N1 with an EC₅₀ of 23 nM. Influenza A virus-IN-14 exhibits low cytotoxicity with CC₅₀ of more than 100 μM. Influenza A virus-IN-14 inhibits cytopathic effect and improves the survival rates of cell Calu3. Influenza A virus-IN-14 exhibits synergistic activity with the neuraminidase inhibitor Oseltamivir (HY-13317). Influenza A virus-IN-14 exhibits poor pharmacokinetic properties in CD-1 mouse .

HY-117387

BFE-37	Endogenous Metabolite	Infection
BFE-37 is a yeast introduction with heat resistance activity. The survival rate change of BFE-37 after heating at 55 °C for 5 minutes was 6.53 log CFU/mL, showing its strong heat resistance in acidic orange juice. The dynamic behavior of BFE-37 at different temperatures showed a first-order logarithmic linear inactivation characteristic, which indicates its stability in heat treatment. The study of BFE-37 helps to understand the effect of mild heat treatment on juice and provide guidance for microbial control in the food industry .

HY-123187

AS2553627	JAK	Cardiovascular Disease
AS2553627 is a type of JAK inhibitor, with IC₅₀ values of 0.46, 0.30, 0.14, and 2.0 nM for JAK1, JAK2, JAK3 and TYK2, respectively. AS2553627 can inhibit the proliferation of human and rat T cells stimulated by IL-2, with IC₅₀ values of 2.4 and 4.3 nM, respectively. AS2553627 can reduce cardiac allograft vasculopathy and fibrosis in a rat heart transplant model, effectively extending survival rates. AS2553627 can be used to prevent acute and chronic rejection in heart transplants .

HY-170839

TRPV1-IN-3	TRP Channel	Inflammation/Immunology
TRPV1-IN-3 (compound 14) is a TRPV1 inhibitor that can be used for the research of idiopathic pulmonary fibrosis. TRPV1-IN-3 affects the expression of fibrosis markers collagen I and α-SMA by inhibiting the TGF-β/Smads and MAPK pathways, thereby exerting antifibrotic activity in vitro (IC₅₀=0.51 μM). TRPV1-IN-3 significantly inhibits collagen deposition in lung tissue, improves the alveolar structure, and also increases the survival rate of mice with pulmonary fibrosis induced by Bleomycin (HY-108345) .

HY-N13866

Cucumarioside A2-2	Others	Cancer
Cucumarioside A2-2 is a triterpene glycoside with antitumor activity. Cucumarioside A2-2 can induce mouse macrophage polarization toward the M1 phenotype. Cucumarioside A2-2 pretreated macrophages can effectively and selectively target and kill multiple types of cancer cells. Cucumarioside A2-2-induced M1 macrophages can effectively target and penetrate tumor tissues and improve the survival rate of mice in an allogeneic model. Exogenous activation of Cucumarioside A2-2 provides a useful model for the subsequent development of antitumor cell immunosuppression .

HY-173309

P53/TLR2 modulator-1	MDM-2/p53 Toll-like Receptor (TLR) Apoptosis MyD88 Bcl-2 Family Interleukin Related	Cancer
P53/TLR2 modulator-1 (Compound Z9) is a modulator that targets both the P53 pathway and TLR2 simultaneously, exhibiting anti-radiation activity. P53/TLR2 modulator-1 reduces apoptosis by inhibiting the radiation-induced expression of P53 and Bax. At the same time, it activates the TLR2 pathway, upregulates the expression of downstream proteins MyD88 and P65, and promotes the secretion of cytokines such as IL-6, thus exerting an anti-radiation effect. P53/TLR2 modulator-1 shows significant anti-radiation activity against both AHH-1 cells and HUVECs. It can also increase the survival rate of C57BL/6J mice irradiated with a lethal dose of radiation and reduce the damage to their hematopoietic system, the villous structure of the small intestine, and the spleen caused by radiation. P53/TLR2 modulator-1 can be used in the research of radiation injury-related diseases .

Cat. No.	Product Name

HY-L184

Anti-Gastric Cancer Compound Library	826 compounds
Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer. MCE designs a unique collection of 826 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

Anti-Gastric Cancer Compound Library

826 compounds

Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer.

MCE designs a unique collection of 826 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

HY-L171

Anti-Hematopathy Compound Library	3,355 compounds
Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs. MCE designs a unique collection of 3,355 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Anti-Hematopathy Compound Library

3,355 compounds

Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs.

MCE designs a unique collection of 3,355 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

HY-L077

Anti-Pancreatic Cancer Compound Library	3,308 compounds
Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer. MCE offers a unique collection of 3,308 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Anti-Pancreatic Cancer Compound Library

3,308 compounds

Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer.

MCE offers a unique collection of 3,308 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area